IASO Biotherapeutics

IASO Biotherapeutics (驯鹿生物) is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel cell therapies and biologics for hematological malignancies and autoimmune diseases. The company leverages its proprietary fully human antibody discovery platform (IMARS), a high-throughput CAR-T drug prioritization platform, and advanced manufacturing processes to develop a diversified pipeline of autologous and allogeneic CAR-T and bispecific antibody product candidates. Its lead asset, Equecabtagene Autoleucel (eque-cel), is an anti-BCMA CAR-T cell therapy that received Breakthrough Therapeutic Designation from China's NMPA and FDA IND approval for U.S. clinical trials. IASO Biotherapeutics was founded in 2017 and operates globally with offices in China and the United States.